2704587-24-4
2704587-24-4
Chemical Structure
Tyk2-IN-8
- CAS No.: 2704587-24-4
- Formula:C20H19D3N8O3
- Molecular Weight:425.46
IUPAC Name: 6-(cyclopropanecarboxamido)-4-((6-(3-(1-hydroxyethyl)azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)amino)-N-methylpyridazine-3-carboxamide
InChIKey: BZZKEPGENYLQSC-HPRDVNIFSA-N
SMILES: [2H]C([2H])([2H])OC1=C(C2=NN(C)C=N2)C=CC=C1NC3=C(N=NC(NC(C4CC4)=O)=C3)C(NC)=O
Biological Activity: Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tyk2-IN-8 | 98.04% | Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC50 of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC50 of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deucravacitinib-13C,d3 | Deucravacitinib-13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deucravacitinib | 99.93% | Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyk2-IN-25 | Tyk2-IN-25 is a TYK2 inhibitor that binds to the JH2 domain of TYK2. Tyk2-IN-25 inhibits p-STAT4 and p-STAT3 in human peripheral blood mononuclear cells. Tyk2-IN-25 is applicable to research related to multiple diseases such as immune and inflammatory diseases, and neurological diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
